- Chemoembolization plus hepatic arterial infusion chemotherapy combined with donafenib, anti-PD-1 antibody for unresectable hepatocellular carcinoma (uHCC): A retrospective analysis.Yin, Linan; Liu, Ruibao; Li, Shijie; Hou, XunboAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Donafenib combined with anti-PD-1 antibodies plus transarterial therapy for initially unresectable hepatocellular carcinomaWen, Yaohong; Fu, Shunjun; He, Guolin; Cai, Lei; Liu, Yahong; Li, Xinmin; Xu, Yuyan; Wang, Chunming; Zhong, Kaihang; Zhang, Cheng; Xie, Qingyu; Pan, MingxinAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Lenvatinib in combination with PD-1 inhibitor and hepatic arterial infusion chemotherapy (HAIC) for patients with potentially resectable hepatocellular carcinoma: A retrospective analysis.Dong, Wei; Zhang, Songyan; Huo, Zhuoni; Lu, Junrong; Liu, Haishi; Wang, Ping; Zhang, YubaoAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
Combination of donafenib and anti-PD-1 antibody plus trans-arterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (uHCC).
3被引9阅读
